Go Deep
ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,669 | -0.8 | 1.21 | 0.07 | 483.05 |
| Oct 2026 | 20,783 | -0.8 | 1.13 | 0.07 | 448.95 |
| Oct 2026 | 18,870 | -0.8 | 1.13 | 0.07 | 450.38 |
| Oct 2026 | 19,105 | -0.7 | 1.06 | 0.07 | 423.83 |
| Oct 2026 | 18,929 | -0.7 | 1.11 | 0.07 | 442.64 |
| Oct 2026 | 18,845 | -0.8 | 1.14 | 0.07 | 451.19 |
ENDRA Life Sciences Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | 159,944.0 | -1,311,433.0 | -3,169,209.0 | -1,595,959.0 |
| EPS | 0.1 | -1.1 | — | -2.1 |
ENDRA Life Sciences Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -7,027,410.0 | -11,507,947.0 | -10,060,250.0 | -13,179,092.0 | — |
| EPS | -8.9 | -56.9 | -2,766.8 | -7,980.0 | — |
ENDRA Life Sciences Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 3,853,797.0 | 4,452,362.0 | 6,754,146.0 | 9,274,147.0 | — |
| Total Liabilities | 1,593,677.0 | 1,891,996.0 | 1,095,157.0 | 2,069,643.0 | — |
| Total Equity | 2,260,120.0 | 2,560,366.0 | 5,658,989.0 | 7,204,504.0 | — |
Owes vs Owns
ENDRA Life Sciences Inc. owed $0.21 for every $1 it owned in Jun 2026, down from $0.22 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.21× | 0.41× | 0.42× | 0.16× | 0.22× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
ENDRA Life Sciences Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 19.8%Fixed assets (tangible) 13.1%Intangible assets 52.2%Other assets 15.0%
How it's funded — Dec 2025
Short-term debt 3.4%Long-term debt 9.4%Payables 9.9%Other liabilities 18.6%Shareholders' equity 58.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 0.8 | 3.2 | 2.8 | 4.9 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 2.6 |
| Fixed assets (tangible) | 0.5 | 0.6 | 0.5 | 0.7 |
| Intangible assets | 2.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.6 | 0.6 | 3.5 | 1.0 |
| Liabilities & equity | ||||
| Short-term debt | 0.1 | 0.1 | 0.0 | 0.0 |
| Long-term debt | 0.4 | 0.5 | 0.2 | 0.4 |
| Payables | 0.4 | 0.3 | 0.4 | 0.6 |
| Other liabilities | 0.7 | 1.0 | 0.5 | 1.1 |
| Shareholders' equity | 2.3 | 2.6 | 5.7 | 7.2 |
| Net tangible assets | 0.3 | 2.6 | 5.7 | 7.2 |
ENDRA Life Sciences Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -5,182,558.0 | -7,400,547.0 | -9,548,775.0 | -12,769,371.0 | — |
| Investing Activities | -3,017,280.0 | -12,796.0 | -24,721.0 | -202,577.0 | — |
| Financing Activities | 5,732,723.0 | 7,808,917.0 | 7,518,305.0 | 8,399,512.0 | — |